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Abstract
Adeno-associated viral (AAV) vectors are the most efficient in vivo gene transfer tools for gene therapy
applications. Efforts have been made to translate encouraging results in small animal models to human
patients. However, the need for large quantities of vector for clinical application remains a great challenge.
Developing novel AAV vectors with enhanced infectivity may reduce the high vector dose requirement for
many applications such as gene therapy for muscular dystrophy. Selective mutation of AAV capsid surface-
exposed tyrosine (Y) is a novel strategy to improve transduction efficiency. AAV6 has been considered one of
the most robust muscle gene delivery vehicles. Here, we hypothesize that AAV6 transduction efficiency can be
further enhanced by mutating surface Y to phenylalanine (F). We found that mutants AAV6-Y445F and AAV6-
Y731F, especially the former, achieved more efficient gene transfer than the original AAV6 after intramuscular
administration to mice. Expression of both firefly luciferase and alkaline phosphatase reporter genes increased
up to 8-fold and DNA copy numbers in muscle increased up to 6-fold. Our results suggest that tyrosine-
mutant AAV6 vectors may represent powerful tools for testing muscle gene therapy in animal models and
potentially in humans.
Introduction
Adeno-associated viral (AAV) vectors have becomepromising vectors for the gene therapy of many genetic
diseases such as hemophilia B (Manno et al., 2003), Leber’s
congenital amaurosis (Maguire et al., 2008, 2009), Parkinson’s
disease (Kaplitt et al., 2007), and hereditary muscular dys-
trophies (Wang et al., 2000; Harper et al., 2002; Yue et al., 2008).
The lack of pathogenicity of the wild-type virus, the broad
tissue tropism, as well as the persistence of vector DNA have
bolstered the potential of AAV as a delivery vehicle for gene
therapy applications (Daya and Berns, 2008).
AAV serotype 2 (AAV2) was the first AAV tested for gene
transfer applications (Samulski et al., 1982). Many studies
have indicated that AAV2 can direct persistent and relatively
strong gene expression in striated muscles (Xiao et al., 1996;
Li et al., 2003; High, 2004). However, the restricted tissue
tropism, low efficiency of gene transfer, slow onset of gene
expression, and highly prevalent preexisting immunity in
human populations have hampered the successful clinical
development of AAV2-based vectors (Gao et al., 2005). To
overcome such drawbacks of rAAV2 vectors, many investi-
gators have begun to explore either naturally occurring
(Gao et al., 2002) or artificially modified (Muzyczka and
Warrington, 2005; Yang et al., 2009) novel AAV capsids,
which are the major determinant of tropism and transduc-
tion efficiency.
For artificially modified AAVs, the novel tyrosine-mutant
AAVs stand out. The tyrosine-mutant AAV2 vector was
first described by Zhong and colleagues (2008). The idea
was originated from the understanding of factors affecting
AAV transduction. The efficiency of AAV transduction
depends on the efficiency at each step of AAV infection:
binding, entry, vial trafficking, nuclear entry, uncoating,
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and second-strand synthesis (Daya and Berns, 2008).
Among them, inefficient AAV trafficking (Hauck et al.,
2004) and second-strand synthesis (Ferrari et al., 1996) have
been identified as rate-limiting factors. It was discovered
that epidermal growth factor receptor protein tyrosine
kinase (EGFR-PTK) signaling negatively affects AAV2
vector transduction by priming capsid ubiquitination and
proteasomal degradation (Zhong et al., 2007). EGFR-PTK
also phosphorylates tyrosine residues on AAV2 capsids. It
was hypothesized that mutations of the surface-exposed
tyrosine residues might allow the vectors to evade phos-
phorylation and subsequent ubiquitination and, thus, pre-
vent proteasome-mediated degradation. Indeed, mutations
of the surface-exposed tyrosine in AAV2 vectors led to
dramatic improvement of transduction efficiency both
in vitro and in vivo (Zhong et al., 2008). Considering the
limitations of AAV2 for future clinical application, testing
alternative tyrosine-mutated AAV serotypes may have
additional translational implications.
To date more than 11 AAV serotypes (Wu et al., 2006) and
more than 100 naturally occurring primate AAV variants
have been reported (Gao et al., 2005). For those reported
AAVs, AAV6 was demonstrated to have superior ability to
transduce skeletal muscles, with greater than 500-fold higher
transduction efficiency than AAV2 vector when the vector
was delivered intramuscularly (Blankinship et al., 2004). In
this study, we compared the transduction efficiency of ty-
rosine-mutant AAV6 vector versus the original AAV6 vector.
The identification of more potent AAV6 vectors will allow
for improved transduction efficiency at a lower dose. This




The original AAV6 packaging plasmid, and the original
AAV8 and AAV9 packaging plasmids, were gifts from
J. Wilson and G. Gao (Bish et al., 2008). Tyrosine-mutant
AAV packaging plasmids were generated by site-directed
mutagenesis as described for AAV2 tyrosine mutants
(Zhong et al., 2008). The cis plasmid pcis.RSV.AP has been
described previously (Yue et al., 2008) and the plasmid pcis-
cmv-luciferase was reported elsewhere (Wang et al., 2008).
Recombinant AAV vectors were generated by triple plas-
mid transfection using pcis.RSV.AP, adenoviral helper
plasmid (pHelper; Stratagene, La Jolla, CA), and the re-
spective packaging plasmids (all carrying the AAV2 rep
gene). For the luciferase vectors, viral stocks were generated
by PEG precipitation followed by double CsCl gradient
purification. For the alkaline phosphatase (AP) vectors,
viral stocks were purified through three rounds of CsCl2
ultracentrifugation. After two changes of dialysis in HEPES
[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] buffer
at 48C for 48 hr, viral genome copy titer was determined by
quantitative PCR and slot blot.
In vivo gene transfer
All animal experiments were approved by the local insti-
tutional animal care and use committee. For the luciferase
studies, 6- to 8-week-old male ICR mice were purchased
from Taconic (Hudson, NY). Various doses of AAV vectors
(31010 vector genomes [VG]/muscle for the low-dose
group, and 31011 VG/muscle for the high-dose group)
were directly injected into tibial anterior (TA) and gastroc-
nemius (Gas) muscles. For AP studies, 5-week-old male
C57BL/6 (BL/6) mice were purchased from Jackson
Laboratory (Bar Harbor, ME). AAV vector was directly in-
jected into the middle belly of the TA muscle at a dose of
5108 vector genomes (VG) of AAV particles (30ml) per muscle.
Optical imaging study
For live animal imaging studies, mice were injected with
luciferase substrate (firefly d-luciferin, 25 mg/ml) (cat. no. NF-
FF-FA; Nanolight Technology, Pinetop, AZ) at 125ml/mouse
3 min before anesthesia. The SOP/guidelines for optimal im-
aging, using the IVIS-100 system (Caliper Life Sciences, Hop-
kinton, MA) at the Biomedical Research Imaging Center of the
University of North Carolina School of Medicine (Chapel Hill,
NC), were strictly followed during the whole process.
Luciferase activity assay
Tissues (25–100 mg) were lysed and homogenized in lu-
ciferase lysis buffer (0.05% Triton X-100, 0.1 M Tris-HCl [pH
7.8], 2 mM EDTA). The homogenized lysate was extensively
vortexed and spun down at 48C for 2 min. The supernatant
was used for luciferase activity analysis. The analysis was
performed according to a previously described protocol (Yu
et al., 2009), and the luciferase assay kit (cat. no. E1501) was
purchased from Promega (Madison, WI).
AP expression analysis
Six weeks after AAV injection, mice were killed and TA
muscles were collected. Half of each TA muscle was em-
bedded in O.C.T. medium for in situ histochemical staining.
Eight-micrometer muscle sections were heated at 658C for
45 min to inactivate endogenous heat-labile AP according to
a published protocol (Ghosh et al., 2007). NIH ImageJ soft-
ware (National Institutes of Health, Bethesda, MD) was used
to quantify the AP-positive region, expressed as a percent-
age, for each muscle section. The remaining half of the TA
muscle was snap frozen in liquid nitrogen. AP activity in
muscle lysate was determined with a StemTAG alkaline
phosphatase activity assay kit (Cell Biolabs, San Diego, CA)
as reported previously (Yue et al., 2008).
Genome copy determination
For the AP studies, genomic DNA was extracted from the
same tissue lysate used for the AP activity assay, using a
salting-out method after overnight proteinase K digestion.
Viral genome copy number was determined with a 7900HT
fast real-time PCR system (Applied Biosystems, Foster City,
CA) as described previously (Yue et al., 2008). For the lucif-
erase studies, total DNA was extracted with a kit purchased
from Qiagen (DNeasy blood and tissue kit, cat. no. 69506;
Qiagen, Valencia, CA). Vector copy number was determined
with a 7300 real-time PCR system (Applied Biosystems).
TaqMan assays for endogenous control of the cystic fibrosis
transmembrane conductance regulator (CFTR) gene (for the
AP study) and the glucagon gene (for the luciferase study)
were developed to normalize vector copy numbers.
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Statistical analysis
Data are presented as means standard error of mean.
Comparison among groups was performed using SPSS
software (SPSS, Chicago, IL). p< 0.05 was considered as
statistically significant.
Results and Discussion
To study the performance of tyrosine-mutant AAV6 vec-
tors, we used two different reporter genes, the firefly lucif-
erase gene driven by the ubiquitous cytomegalovirus (CMV)
promoter (Wang et al., 2008; Yu et al., 2009) and the human
placental alkaline phosphatase (AP) gene driven by the
ubiquitous Rous sarcoma virus (RSV) promoter (Yue et al.,
2008). Similar to approaches described elsewhere (Zhong
et al., 2008), site-directed mutagenesis was performed to
generate surface-exposed single tyrosine-mutant AAV6 vec-
tors, AAV6-Y445F and AAV6-Y731F. In both mutants, the
corresponding surface-exposed tyrosine (Y) residue was re-
placed with phenylalanine (F).
We generated AAV6 and tyrosine-mutant AAV6 vectors
containing the firefly luciferase reporter gene: AAV6-Luc,
AAV6-Y445F-Luc, and AAV6-Y731F-Luc. The viruses were
purified by PEG precipitation followed by double CsCl
gradient purification. The vector titer generated from tyro-
sine-mutant plasmids was similar to that of the original
AAV6 packaging plasmid, which indicated that modification
of tyrosine to phenylalanine did not affect their packaging
capacity. We then tested the functionality of tyrosine-mutant
AAV6 vectors in vivo. For muscle-directed gene therapy,
intramuscular injection of AAV vector is a valuable approach
to achieve robust transgene expression in skeletal muscle.
We therefore used this method to examine the performance
of tyrosine-mutant AAV6 vectors. The mice were divided
into three groups, with three mice in each group. For each
mouse, we delivered a relatively lower dose to the left leg
(31010 VG/injection site in a 50-ml volume, two sites for
each leg) and a 10-fold higher dose to the right leg (31011
VG/injection site in a 50-ml volume, two sites for each leg).
The two injection sites were located in the middle of the
tibialis anterior (TA) and gastrocnemius (Gas) muscles. Three
weeks after vector delivery, the live mice were subjected to
optical imaging to examine luciferase intensity. As shown in
Fig. 1A, the luciferase signal of the right leg (high dose) was
stronger than that of the left leg. More importantly, the lu-
ciferase signal of mice injected with the tyrosine-mutant
vectors (AAV6-Y445F and AAV6-Y731F) was much stronger
than that of the mice injected with the original AAV6 vector.
We then killed the mice and carefully dissected the TA and
Gas muscles. Half the muscle tissue was subjected to lucif-
erase activity assay, and the other half was used for DNA
extraction and quantification of vector copy numbers. The
luciferase activity assay showed that the tyrosine-mutant
AAV6 vectors resulted in 8- to 10-fold higher luciferase ac-
tivity than that of the original AAV6 vector in both the low-
dose and high-dose groups (Fig. 1B) ( p< 0.05). Quantitation
FIG. 1. Tyrosine-mutant AAV6-Luc vectors mediate more robust expression in muscle via intramuscular injection. (A)
Optical imaging of luciferase gene expression in living mice. We delivered AAV vectors into two sites for each leg. For the left
leg, a relative low dose (31010 VG/site) was used; for the right leg, a high dose (31011 VG/site) was injected. (B) Luciferase
activity generated from the tissues injected with wild-type and tyrosine-mutant AAV vectors. The tibialis and gastrocnemius
muscles were carefully dissected when the animals were killed, and their lysates were subjected to luciferase activity assay
(see Materials and Methods for details). (C) Quantitation of viral genome copy numbers. Real-time PCR indicated that there
were more genome copy numbers in the muscles injected with tyrosine-mutant AAV6 vectors. The results shown here were
generated from TA muscles injected with high doses of vectors. The glucagon gene was used for normalization. Vector copy
numbers are displayed as vector copies per cell. Low-dose group, p> 0.05; high-dose group, p< 0.01. Color images available
online at www.liebertonline.com/hum.
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of real-time PCR indicated that there were more genome
copy numbers (4- to 6-fold more) in the tyrosine-mutant
groups than in the original AAV6 group, particularly in the
high-dose groups (Fig. 1C) ( p< 0.01).
To further test the tyrosine-mutant AAV6 vectors, we used
a different reporter gene, the human placental alkaline
phosphatase (AP) gene. AAV vectors were purified by three
rounds of isopycnic ultracentrifugation in CsCl gradient in a
different laboratory and the experiments were performed
independently from those of the luciferase studies. This time,
we used much lower vector doses. AAV vector was directly
injected into the middle belly of the tibialis anterior (TA)
muscle at a dose of 5108 VG of AAV particles (30ml) per
muscle. Six weeks after AAV injection, mice were killed and
the TA muscles were collected. Half of each TA muscle was
embedded in O.C.T. medium for in situ histochemical
staining, and the remaining half of the TA muscle was snap
frozen in liquid nitrogen for AP activity assay and vector
copy number analysis. For in situ histochemical staining, 8-
mm cryosections were heated at 658C for 45 min to inactivate
endogenous heat-labile AP, and the staining were performed
according to a published protocol (Ghosh et al., 2007). The
results are displayed in Fig. 2A. The tyrosine-mutant AAV6-
Y445F vector showed the highest AP expression, followed by
the tyrosine-mutant AAV6-Y731F and the original AAV6
vector. On quantification (from three independent locations
of the TA muscle including the proximal end, middle belly,
and the distal end), AAV6-Y445F, Y731F-AAV6, and the
original AAV6 resulted in 87.5 3.1, 66.2 3.9, and
41.6 4.4% AP-positive areas, respectively (Fig. 2B). We then
analyzed AP activity with the StemTAG alkaline phospha-
tase activity assay kit (Cell Biolabs) as described elsewhere
(Yue et al., 2008). Consistent with the histochemical staining
results, tissues injected with the tyrosine-mutant AAV6-
Y445F vector displayed the highest AP activity (88.3
22.3 mM/mg), followed by tissues injected with tyrosine-
mutant AAV6-Y731F (39.8 7.5 mM/mg); the original AAV6
vector resulted in only 9.4 1.3 mM/mg AP activity (Fig. 2B).
Last, we extracted total DNA from those samples and per-
formed quantitative PCR to determine vector copy numbers.
As expected, both tyrosine-mutant groups (AAV6-Y445F and
AAV6-Y731F) demonstrated a significant higher copy num-
ber of AAV genomes than did the original AAV6 vector
group (Fig. 2B, p< 0.05).
In summary, consistent results were obtained from two
independent laboratories using two different reporter genes,
the firefly luciferase gene and the AP gene. Collectively, the
tyrosine-mutant AAV6 vectors mediated much stronger
transgene expression than did the original AAV6 vector after
direct muscle injection. Further, AAV6-Y445F appeared to
lead to better transduction than AAV6-Y731F. Both AAV6-
Y445F and AAV6-Y731F demonstrated significant higher
vector copy numbers in injected muscles. Our data suggest
that mutating the surface tyrosine residues may represent a
valid strategy to significantly enhance the transduction effi-
ciency of AAV serotypes other than AAV2.
One of the drawbacks for AAV vectors is that it is often
necessary to use large amounts of viral particles to achieve
sufficient levels of transgene expression (Zhong et al., 2008).
This presents a particular challenge for large animal studies
and human clinical applications. In these cases, up to 1015
VG particles are required even for a single experiment. It is
costly and labor-intensive to produce large quantities of
AAV vectors. Our results here suggest that we may be able
to achieve a similar expression level with an at least sever-
alfold lower dose were we to package the therapeutic ex-
pression cassettes in a tyrosine-mutant capsid. This would
not only ease the burden of vector production, but would
also add to the safety of AAV gene therapy because of the
reduced vector load.
Our luciferase and AP reporter gene studies suggest that
there were more vector genome copy numbers in the muscles
FIG. 2. Analysis of alkaline
phosphatase (AP) expression and
AAV genome copy after local in-
jection of original and tyrosine-
mutant AAV6 vectors carrying the
AP gene. (A) Representative pho-
tomicrographs for each set of vec-
tors. Scale bar applies to all images.
(B) Quantification of AP-positive
areas in muscle sections (n¼ 4 or 5
for each group), AP activity in
whole muscle lysate (n¼ 3 or 4 for
each group), and AAV genome
copy (n¼ 3 for each group). For
endogenous control and genome
copy normalization, we used a pair
of primers specific for the mouse
CFTR gene. The genome copy
number is expressed as viral ge-
nome copies per diploid nuclear
genome. *Significantly different
from other groups ( p< 0.02).
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injected with tyrosine-mutant AAV6 vectors compared with
wild-type AAV6-injected muscles. The exact molecular
mechanisms remain to be investigated. Nevertheless, we
speculate that it may involve less vector degradation and/or
improved intracellular trafficking. In the case of the AAV2
vector, the selective mutation of surface-exposed tyrosine
bypasses the ubiquitination step, significantly enhancing in-
tracellular trafficking and entry of the viral genome into the
nucleus (Zhong et al., 2008). It is possible that modulation of
the AAV6 capsid may also evade phosphorylation, ubiqui-
tination, and subsequent proteasome-mediated degradation,
thus improving intracellular trafficking and nuclear trans-
port of viral particles.
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